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Abstract: Huntingtin-interacting protein 1 (HIP1) has recently 
been identified as a new fusion partner fused to anaplastic lym-
phoma kinase (ALK) in non–small-cell lung cancer (NSCLC). To 
date, two variants of HIP1-ALK (H21; A20) and (H28; A20) have 
been identified in NSCLC. However, the response of patients with 
NSCLC harboring HIP1-ALK to ALK inhibitors and potential 
resistance mechanisms to such remain unknown. Here, we report 
a patient with NSCLC harboring a novel HIP1-ALK fusion variant 
(H30; A20). This patient and another patient with EML4-ALK variant 
3a/b initially responded sequentially to crizotinib and then alectinib, 
a next-generation ALK inhibitor, but developed acquired resistance 
to alectinib with the presence of a mutation in amino acid residue 
1171 (I1171N and I1171S respectively) located in the hydrophobic 
regulatory spine (R-spine) of the ALK kinase in both the cases as 
identified by a comprehensive next-generation sequencing-based 
assay performed on biopsies of new liver metastases that developed 
during alectinib treatment.
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(J Thorac Oncol. 2014;9: 1821–1825)
Crizotinib, a multitargeted anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1)/Met proto-oncogene 
(MET) tyrosine kinase inhibitor has demonstrated signifi-
cant improvements in response rate progression-free survival 
as compared with cytotoxic chemotherapy as either first-line 
or second-line treatment of patients with ALK-rearranged 
 non–small-cell lung cancer (NSCLC) diagnosed based on an 
U.S. Food and Drug Administration–approved fluorescence in 
situ hybridization test.1,2 However, resistance to crizotinib invari-
ably develops and many next-generation ALK inhibitors are 
in development. ALK-rearranged NSCLC is a heterogeneous 
molecular subgroup of lung cancer with at least four known 
fusion partners identified (EML4-, KIF5B-, TFG-, KLC1-).3 
Recently Huntingtin-interacting protein-1 (HIP1) was the latest 
and fifth fusion partner identified to be fused to ALK in NSCLC 
with two different HIP1-ALK variants reported (H28; A20) and 
(H21; A20) to date. 4,5 Analogous to the known multiple variants 
of EML4-ALK, it is likely that other HIP1-ALK fusion variants 
exist in NSCLC also. Here, we describe a patient with NSCLC 
harboring a novel HIP1-ALK fusion variant together with another 
patient with EML4-ALK variant 3a/b both of whom have been 
treated with crizotinib and then alectinib in which secondary 
mutations at amino acid residue 1171 in the hydrophobic regula-
tory-spine (R-spine) of the ALK kinase domain were identified.
CASE DESCRIPTIONS
Case one is that of a Dutch-Indonesian female never 
smoker who was diagnosed with de novo stage IV NSCLC 
adenocarcinoma at age 58. Her tumor was found to be positive 
for ALK-rearrangement by fluorescence in situ hybridization 
and she was enrolled onto PROFILE 1014 (NCT01154140) 
(crizotinib versus platinum/pemetrexed in treatment-naive 
advanced  ALK-rearranged NSCLC) and was randomized to 
receive crizotinib. She had a partial response (PR) although on 
crizotinib but developed progression after 5 months. She was 
then enrolled onto the phase 1 dose escalation portion of the 
alectinib trial (AF-002JG, NCT01588028) at 900 mg orally 
twice daily. No rebiopsy was performed after crizotinib pro-
gression. Prealectinib baseline positron emission tomography-
computed tomography scan showed the progressive disease in 
the mediastinum but no evidence of liver metastases (Fig. 1A). 
The washout period from the last dose of crizotinib to the first 
dose of alectinib was 20 days. She tolerated the alectinib dose 
well  without any adverse events, dose interruption or dose 
DOI: 10.1097/JTO.0000000000000368 
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/14/0912-1821
Identification of a Novel HIP1-ALK Fusion Variant in 
Non–Small-Cell Lung Cancer (NSCLC) and Discovery of 
ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged 
NSCLC Patients with Resistance to Alectinib
Sai-Hong Ignatius Ou, MD, PhD,* Samuel J. Klempner, MD,* Joel R. Greenbowe, BS,†  
Michele Azada, MPH,* Alexa B. Schrock, PhD,† Siraj M. Ali, MD, PhD,† Jeffrey S. Ross, MD,†‡  
Philip J. Stephens, PhD,† and Vincent A. Miller, MD†
*Division of Hematology-Oncology, Department of Medicine, Chao Family 
Comprehensive Cancer Center, University of California Irvine School of 
Medicine, Orange, California; †Foundation Medicine, Inc., Cambridge, 
Massachusetts; and ‡Departmente of Pathology and Laboratory Medicine, 
Albany Medical Center, Albany, New York.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Sai-Hong Ignatius Ou, MD, PhD, Department 
of Medicine, Division of Hematology-Oncology, Chao Family 
Comprehensive Cancer Center, University of California Irvine School of 
Medicine, Orange, CA 92868. E-mail: Ignatius.ou@uci.edu
BRIEF REPORT
1822 Copyright © 2014 by the International Association for the Study of Lung Cancer
Ou et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014
reduction, and achieved a confirmed complete response (CR) 
after 2 months on alectinib that lasted for 12 months after 
starting alectinib when several new liver lesions were noted 
(Fig. 1B). Computed tomography–guided needle biopsy of a 
liver metastasis confirmed adenocarcinoma and was subjected 
to genomic profiling through clinical grade next-generation 
sequencing assay (FoundationOne, Foundation Medicine, 
Inc., Cambridge, MA ) as previously described.6 These results 
revealed that this tumor specimen harbored a new HIP1-ALK 
fusion variant involving rearrangement and fusion of exons 1 
to 30 of HIP1 to exons 20 to 29 of ALK (H30; A20) (Fig. 2). 
In addition, a single amino acid substitution at position 1171 
changing the hydrophobic isoleucine residue to a hydrophilic 
asparagine residue was comprising approximately 15% of 
the sequencing runs was identified where tumor purity in the 
biopsy sample was estimated to be 30% (Fig. 3A).
Case 2 is that of a Caucasian male never-smoker who was 
diagnosed with stage IV ALK-rearranged NSCLC at age 38. 
A
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FIGURE 1. A, Prealectinib positron emis-
sion tomography-computed tomography 
scan treatment of the patient (case 1) 
showing disease progression in the medi-
astinum and lungs but no liver involve-
ment. The red circle indicated the location 
of metastatic disease upon progression 
with crizotinib. B, Serial computed tomog-
raphy of the abdomen of the patient (case 
1) showing the appearance of several 
liver lesions after 12 months of alectinib 
treatment. The red circle represents where 
the rebiopsy of the tumor was performed. 
C, Prealectinib baseline scan and on-
treatment scan of patient (case 2) which 
showed the emergence of a new liver 
metastasis after 12 months of alectinib 
treatment. Arrows indicate liver metastasis.
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He was enrolled onto single-arm crizotinib trial PROFILE1005 
(NCT00932451) and received crizotinib 250 mg twice daily. He 
achieved a confirmed PR after 5 months but developed both 
intrathoracic progression and asymptomatic brain metastasis 
after 21 months of crizotinib treatment. He was then enrolled 
onto the same trial as the patient in case 1 and received alectinib 
900 mg twice daily. The period between the dose of crizotinib 
and the first dose of alectinib was 15 days. The alectinib dose 
was eventually reduced to 750 mg twice daily after 4 months 
of treatment due to headache. He achieved a PR with alectinib 
treatment after 6 weeks but after 12 months of alectinib treat-
ment a new 18-fluorodeoxyglucose-avid liver lesion was identi-
fied (Fig. 1C), a biopsy of which was done and assayed with 
FoundationOne. The tumor purity in the sample was estimated 
to be 70%. The analysis revealed the EML4-ALK 3a/b variant 
and a base substitution occurring at 36% frequency in the codon 
encoding amino acid residue 1171 that resulted in the substitu-
tion of isoleucine to serine (I1171S) (Fig. 3B).
DISCUSSION
Here we report a novel HIP1-ALK (H30; A20) fusion 
transcript, the third HIP1-ALK fusion variant described in 
NSCLC to date. The fusion breakpoint of HIP1 at intron 29 
is the same breakpoint as the Huntingtin-interacting  protein 
 1-platelet-derived growth factor receptor beta  (HIP1-PDFGRβ) 
gene fusion in chronic myelomonocytic leukemia , the only other 
malignancy where HIP1 has been reported to be rearranged to 
kinases leading to aberrant signaling and malignant transfor-
mation.7 The full-length HIP1 protein contains 1037 amino 
acids encoded by 31 exons and contains an AP180 N-terminal 
domain between the amino acids 32 to 160, a coiled-coil 
domain between amino acids 368 to 644, and a talin-homology 
domain between 771 to 1012 amino acids. Within the coiled-
coil domain there is also a pseudo dia-autoregulatory domain 
(pDAD) domain that may mediate apoptosis.8 HIP1-ALK (H30; 
A20) is generated by in-frame rearrangement and fusion of the 
exons 1 to 30 of HIP1 to exon 20 to 29 of ALK resulting in a 
fusion lacking only 18 amino acids of the c-terminal domain 
of HIP1 and retaining all the three functional domains of HIP1 
(AP180 N-terminal, coiled-coil, talin-homology) (Fig. 2). Fang 
et al.4 has demonstrated that HIP1-ALK (H28; A20) is respon-
sive to crizotinib in vitro whereas Hong et al.5 treated their 
HIP1-ALK (H21; A20) patient with adjuvant crizotinib after 
complete surgical resection with no recurrence at the time of 
FIGURE 2.  Diagrammatic representation of the rearrangement involved exons 1 to 30 of Huntingtin-interacting protein 1 
(HIP1) and exons 20 to 29 of anaplastic lymphoma kinase (ALK). Two previously identified HIP1-ALK fusion variants were also 
shown. ANTH, AP180 N-terminal; CC, coiled coil domain of the HIP1 protein; TH, talin-homology.
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their report but cannot confirm that the lack of recurrence is 
due to crizotinib. The current report is the first to describe that a 
patient with NSCLC harboring the HIP1-ALK fusion variant is 
responsive to multiple ALK inhibitors.
Isoleucine to asparagine change at amino acid residue 
1171 in the ALK kinase domain (1171N) was first identi-
fied as a rare activating mutation in familial neuroblastoma.9 
Mutations at amino acid residue 1171 (I1171T/N/S/I) was 
FIGURE 3. A, Diagrammatic representation of the I1171N mutation identified from case 1 indicating approximately 15% of 
the next generation sequencing run showed the presence of resistant I1171N substitution. B, Diagrammatic representation of 
the I1171S mutation identified from case 2 indicating approximately 36% of the next-generation sequencing run showed the 
presence of resistant I1171S substitution.
1825Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014 Identification of a Novel HIP1-ALK Fusion Variant
also identified as one of the most common acquired resistance 
mechanisms from an in vitro acceleration mutagenesis screen 
in  EML4-ALK cell lines in the presence of increasing concen-
tration of crizotinib.10 Furthermore, I1171N was also identified 
from a resistance selection assay in a  nucleophosmin-anaplastic 
lymphoma kinase (NPM-ALK) cell line (SPU-M2) that con-
fer high level of acquired resistance to several ALK inhibitors 
(crizotinib, AP26113, TAE684).11 When engineered into Ba/F3 
NMP-ALK cell lines, I1171N results in 6 to 127 fold increase 
in the concentration that inhibits 50% (IC
50
) against the same 
three ALK inhibitors.11 When Zdzalik et al. separately selected 
for Karpas299 (driven by NPM-ALK rearrangement) cell line 
that is resistant to crizotinib (Karpas299 CR), an I1171T muta-
tion emerged that increased the IC
50
 to both crizotinib and 
alectinib by at least 10 fold.12 Consistent with this, our cases 
indicated that I1171X can also confer resistance to alectinib 
as I1171N/S were both identified from new liver metastases. 
These liver metastases were neither present during the initial 
crizotinib treatment nor present during the first 12 months of 
alectinib treatment in both the patients. Amino acid residue 
1171 is situated on the hydrophobic regulatory spine (R-spine) 
that connects the two major lobes of the ALK kinase and 
I1171N results in ALK kinase preferentially in the active con-
formation.13 The inhibitory activity of alectinib against many 
of the known acquired ALK mutations was recently published 
but I1171N was not among the ALK mutations described.14 
Despite the in vitro data and clinical presentation, notably we 
could not definitively conclude that mutation at I1171 confers 
resistance to alectinib as tumor specimens after crizotinib and 
before alectinib treatment was not available. However, the 
characterization of Karpas299CR (I1171T) cells strongly sug-
gests that if the presence of a I1171X mutation appeared dur-
ing and confer resistance to crizotinib treatment before the use 
of alectinib, the I1171 mutation would have conferred resis-
tance to alectinib and not the prolonged CR and PR observed 
with alectinib in our two patient cases.
Recently another second generation ALK inhibitor, ceri-
tinib may be able to overcome acquired resistance conferred 
by an I1171T mutation.15 An implication of this finding is that 
doing a rebiopsy of the NSCLC cases with acquired resistance 
to targeted therapy can provide additional treatment options. 
Furthermore, from the results of the sequencing runs only a 
portion of the tumor samples harbored the resistance I1171 
mutation from our two patients cases respectively indicating 
the tumors in both of our patients likely continue to depend on 
ALK signaling and switching to another ALK inhibitor that 
can potentially overcome I1171X resistance such as ceritinib 
may be the optimal approach for our two patients.
In summary, comprehensive and fully informative 
genomic profiling allows the identification of both known and 
novel ALK fusion partners and variants, and alterations in the 
ALK gene that underlie acquired resistance and which can be 
targeted to likely further benefit patients who have progressed 
on first-line or even second-line targeted therapy.
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